Manufacturer: Dragon Pharma
Pharmaceutical name: Sermorelin
Pack: 1 vial (5 mg)
Sermorelin is a biologically active version of growth hormone-releasing hormone (GHRH) produced by the human brain, which triggers the pituitary gland to produce and release growth hormone. It promotes the body’s own secretion of HGH. Sermorelin is a shortened form of growth hormone-releasing factor (GRF 1-44), naturally synthesized in the brain to encourage the pituitary gland to emit HGH. In younger years, the brain produces sufficient GHRH, enabling the pituitary to supply the body with enough growth hormone necessary for health, energy, and normal physiological functions. However, as age increases, GHRH production diminishes, resulting in a decrease in the production and release of HGH from the pituitary, which amplifies the effects of growth hormone deficiency.
Unlike HGH, Sermorelin targets a more fundamental issue in the GH neuroendocrine system, offers more physiological benefits, has an improved safety profile, and is not restricted for use in treating adult hormone deficiency. While Sermorelin produces similar outcomes on body composition and provides additional advantages like HGH, it also offers some significant extra benefits. The impact of Sermorelin is managed at the pituitary gland level through negative feedback and somatostatin release, which helps minimize or completely prevent safety issues linked to HGH overdoses. The release of HGH from the pituitary, in response to Sermorelin, occurs in an episodic manner instead of a continuous "square wave," thus avoiding tachyphylaxis by imitating normal physiological patterns. By stimulating the pituitary, it helps to maintain more of the growth hormone neuroendocrine axis, which tends to be the first system to deteriorate with aging.